NCT03639311 - Phase 2b, Open-label, Multicenter, Rollover Study to Assess Antiviral Activity and Safety of Long-acting (LA) Cabotegravir (CAB) Plus LA Rilpivirine (RPV), Administered Every 2 Months (Q2M), in Human Immunodeficiency Virus (HIV)-Positive Participants From the LATTE Study | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

September 24, 2018

Primary Completion Date

December 11, 2019

Study Completion Date

January 30, 2023

Conditions

HIV Infections

Interventions

DRUG

CAB LA

Administered CAB LA (600 mg) Q2M, as intramuscular injection.

DRUG

RPV LA

Administered RPV LA (900 mg), Q2M, as intramuscular injection.

DRUG

RPV

Oral dose of RPV 25 mg, administered once daily from Day 1 up to Month 12

DRUG

DTG

Oral dose of DTG 50 mg administered once daily from Day 1 up to Month 12.

Trial Locations (30)

10032

GSK Investigational Site, New York

10065

GSK Investigational Site, New York

14215

GSK Investigational Site, Buffalo

20007

GSK Investigational Site, Washington D.C.

20037

GSK Investigational Site, Washington D.C.

22003

GSK Investigational Site, Annandale

29425

GSK Investigational Site, Charleston

31201

GSK Investigational Site, Macon

31401

GSK Investigational Site, Savannah

32803

GSK Investigational Site, Orlando

33316

GSK Investigational Site, Fort Lauderdale

33407

GSK Investigational Site, West Palm Beach

34982

GSK Investigational Site, Ft. Pierce

46202

GSK Investigational Site, Indianapolis

68198

GSK Investigational Site, Omaha

75246

GSK Investigational Site, Dallas

78705

GSK Investigational Site, Austin

80209

GSK Investigational Site, Denver

85015

GSK Investigational Site, Phoenix

89106

GSK Investigational Site, Las Vegas

90069

GSK Investigational Site, Los Angeles

90211

GSK Investigational Site, Beverly Hills

90813

GSK Investigational Site, Long Beach

93301

GSK Investigational Site, Bakersfield

30912-3130

GSK Investigational Site, Augusta

V6Z 2T1

GSK Investigational Site, Vancouver

M4N 3M5

GSK Investigational Site, Toronto

M5G 1K2

GSK Investigational Site, Toronto

H2L 4E9

GSK Investigational Site, Montreal

H3A 1T1

GSK Investigational Site, Montreal